Lymphokine-Activated Killer (LAK) Cells. More recent studies have demonstrated that LAK cells are derived from either NK or T lymphocytes, although in the blood of normal human donors, NK cells are the predominant precursor cells. B cells or monocytes do not give rise to LAK cells. In cell biology, a lymphokine-activated killer cell (also known as a LAK cell) is a white blood cell that has been stimulated to kill tumor cells. If lymphocytes are cultured in the presence of Interleukin 2, it results in the development of effector cells which are cytotoxic to tumor cells. Leukocytes in blood and spleen can be activated by interleukin 2 (IL-2) to become cytotoxic to certain tumor cell lines in vitro. Recent evidence suggests that.


Author: Princess Treutel DDS
Country: Burundi
Language: English
Genre: Education
Published: 4 December 2017
Pages: 724
PDF File Size: 6.77 Mb
ePub File Size: 49.62 Mb
ISBN: 397-9-41962-164-7
Downloads: 93778
Price: Free
Uploader: Princess Treutel DDS


Cytotoxicity of LAK cells. Lymphokine activated killer cells LAK cells were co-cultured with the target H cells with or without Ad-p53 infection, for 6 h at effector: Ad-p53 infection significantly increased the percentage of specific cell lysis at all effector: The highest percentages of cell lysis were observed at 50 MOI of Ad-pinfected H cells, and both 20 MOI and 50 MOI of Ad-pinfected cells led to significantly higher cytotoxicity than that for the non-infected cells.

Immunotherapy for cancer: the use of lymphokine activated killer (LAK) cells.

In a new window Figure 3. Cytotoxicity assay of lymphokine-activated killer LAK cells against H cells in vitro. Significantly higher percentages of specific cell lysis were observed in all Ad-pinfected H cells at all effector: Previous Section Next Section Lymphokine activated killer cells To date, a number of cytotoxic effector cell expansion protocols have been reported, including those employing LAK cells and cytokine-induced killer cells CIK 2316 These lymphokine activated killer cells are similar to the data provided by the company Kohji Bio, Saitama, Japan which produces the medium used for LAK cell cultivation in this study.

Although Ad-p53 gene therapy has been intensively studied for the treatment of head and neck cancer, and has demonstrated efficacy in local control of tumor growth 5there is no clinical randomized control trial showing prolongation of overall survival.

In our in vitro study, Ad-p53 showed significant cytotoxicity in H, a human hypopharyngeal cancer cell line, at day 6 at MOI Figure 2. We considered that this cytotoxicity did not affect the results of the cytotoxicity assay for LAK cells in H target cells infected lymphokine activated killer cells 20 or 50 MOI of Ad-p53 at 30 h after infection.

Therefore, the results of our LAK cell cytotoxicity assay suggest lymphokine activated killer cells Ad-p53 infection can significantly enhance the cytotoxicity of LAK cells Figure 3. In a new window Figure 4. The interaction between the receptors on immune effector cells and the ligands on target tumor cells is considered to play a major role in the activation of antitumor immunity.

Lymphokine-activated killer cell - Wikipedia

ULBPs are well-known as ligands of NKG2D 9and it has been reported that pharmacological reactivation of p53 induced by the protein reactivation of p53 and induction of tumor cell apoptosis can stimulate ULBP2 Perhaps lymphokine activated killer cells overexpression of p53 induced by Ad-p53 might differently stimulate NKG2D ligand expression on tumor cells due to stimulation by the pharmacological reactivation of p The anti-tumor lymphokine activated killer cells of lymphokine-activated killer cells and recombinant interleukin 2 in vivo.

Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cells.

Immunotherapy for cancer: the use of lymphokine activated killer (LAK) cells.

Recombinant interleukin 2 enhanced natural killer cell-mediated cytotoxicity in human lymphocyte subpopulations expressing the Leu 7 and Leu 11 antigens. The fate of interleukin-2 after in vivo administration. Dissection of the lymphokine-activated lymphokine activated killer cells phenomenon.

Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis.

Definition of lymphokine-activated killer cells - NCI Drug Dictionary - National Cancer Institute

A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Eradication of a disseminated syngeneic mouse lymphoma by lymphokine activated killer cells adoptive transfer of immune lymphocytes and its dependence upon a host component s.

Toxicity of recombinant human interleukin-2 in rats following intravenous infusion.


Induction of endogenous cytokine-mRNA in circulating peripheral blood mononuclear cells by IL-2 administration to cancer patients. Cytokine gene expression during the generation of human lymphokine-activated killer cells: Patterns of cytokines released lymphokine activated killer cells peripheral blood leukocytes of normal donors and cancer patients during interleukin-2 activation in vitro.


J Biol Response Mod.

Related Post: